Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The Company is focused on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). It intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. It is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.